BRL-302

BRL-302 is an allogeneic (universal) CAR-T cell therapy developed by Bioray Laboratories that simultaneously targets B-cell maturation antigen (BCMA) and CD19. Designed as an "off-the-shelf" product, it utilizes genetically engineered T cells derived from healthy donors, which eliminates the need for individualized patient manufacturing. The therapy is currently being evaluated in a Phase 1 clinical trial for the treatment of refractory AQP4-antibody positive neuromyelitis optica spectrum disorder (NMOSD). Its dual-targeting approach is intended to deplete both CD19-expressing B cells and BCMA-expressing plasma cells, thereby reducing the production of pathogenic autoantibodies that drive the neuroinflammatory pathology of NMOSD.

Other names

Universal BCMA-CD19 CAR-TUniversal BCMA-CD19 CARTallogeneic BCMA-CD19 CAR-T